The total return over the past 12 months is +77.82% vs. +19.98% for the S&P 500. So far it's up +44.63% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +77.82% | +11.20% | (8.49%) | +13.07% | +15.84% | +10.24% |
| Total Return CAGR | +77.82% | +11.20% | (8.49%) | +13.07% | +15.84% | +10.24% |
| Revenue CAGR | (0.74%) | (0.70%) | +4.08% | +10.36% | +8.86% | +6.43% |
| Net Income CAGR | N/A | (70.24%) | (47.23%) | (22.19%) | N/A | (10.26%) |
| EPS CAGR | N/A | (70.56%) | (47.86%) | (22.99%) | N/A | (10.43%) |
| Free Cash Flow CAGR | (35.94%) | +9.62% | +6.43% | +4.15% | +7.14% | +7.87% |
| Operating Cash Flow CAGR | (26.07%) | (2.24%) | (2.84%) | +6.66% | +8.54% | +5.35% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Charles River Laboratories International, Inc. (CRL)
| Year | Start price | End price | CRL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $199.48 | $288.50 | +44.63% | +13.55% | +31.08% |
| 2025 | $184.60 | $199.48 | +8.06% | +17.72% | (9.66%) |
| 2024 | $236.40 | $184.60 | (21.91%) | +24.89% | (46.80%) |
| 2023 | $217.90 | $236.40 | +8.49% | +26.19% | (17.70%) |
| 2022 | $376.78 | $217.90 | (42.17%) | (18.17%) | (24.00%) |
| 2021 | $249.86 | $376.78 | +50.80% | +28.74% | +22.06% |
| 2020 | $152.76 | $249.86 | +63.56% | +18.37% | +45.19% |
| 2019 | $113.18 | $152.76 | +34.97% | +31.22% | +3.75% |
| 2018 | $109.45 | $113.18 | +3.41% | (4.56%) | +7.97% |
| 2017 | $76.19 | $109.45 | +43.65% | +21.70% | +21.95% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
